Slide 1: Q1/2026 Results
“@Prodalim Creating Natural Solutions Q1/2026 Results MAY 2026
Slide 2: Disclaimer
Disclaimer This presentation does not constitute and should not be construed as an offer or invitation to purchase and / or allocate securities of the Company. The presentation has been prepared for the purpose of summary and convenience only and is not intended for nor can it replace a review of th
Slide 3: Our platform at a glance
Our platform at a glance 39 Years of expertise $344M Revenues ~50 countries + Sourcing * since 1987 16 Global sites 570 Employees 1200+ Products 700+ Customers 60+ Countries 47% ** 5Y revenues CAGR worldwide in high value solutions REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 003 * L
Slide 4: Moving up in the value chain while leveraging our core assets
Long term & intimate Integrated tree- relationships with top tier Tailor Made to table supply Solutions F&B customers chain Moving up in the Specialty Ingredients value chain while leveraging our Juice Solutions core assets REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 004
Slide 5: Significant expansion in addressable market & profit margin
Significant expansion in addressable market & profit margin Market Juice Solutions Growth F&B & Specialty $15B TAM >4x TAM Ingredients $65B TAM Avg EBITDA% 10%-15% Profitability 15%-25% +500 -1,500 bp REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 005 Source: Prodalim internal resource
Slide 6: Consistent accelerated growth within Specialty Ingredients & Solutions (SIS)
Consistent accelerated growth within Specialty Ingredients & Solutions (SIS) Revenues in $M 77 ** 62 * 16 2021 2022 2023 2024 2025 2026 REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 006 * Including René Laurent (acquired in December 2025) on a pro-forma basis ** LTM ended in Q1’2026 o
Slide 7: Growing share of profitable activities
Growing share of profitable activities % of SIS out of total Group SIS Revenue % Share SIS EBITDA % Share * 36% 21% 11% 9% Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 007 * Based on Adjusted EBITDA ; Q1-Q2'2024 are based on unrev
Slide 8: Profitable growth in Specialty Ingredients & Solutions
Profitable growth in Specialty Ingredients & Solutions M USD Q1 Revenues Q1 EBITDA* * EBITDA EBITDA % 19.7 18.2% 6.0 20.0% 5.0 15.3% 15.0% 12.0 4.0 3.6 9.0% 3.0 10.0% 9.2 1.8 2.0 0.8 5.0% 1.0 0.0 0.0% 1 2 3 Q1’2024 Q1’2025 Q1’2026 Q1’2024 Q1’2025 Q1’2026 REVENUES EBITDA Q1’2026: $19.7M Q1’2026: $3.6
Slide 9: Financial Performance
Financial Performance Q1 REPORT MAY 2026
Slide 10: P&L highlights
P&L highlights M USD Group Q1’2026 Q1’2025 Δ Total Sales 91.5 87.7 4.4% Gross profit 17.3 16.5 4.8% % 18.8% 18.8% Adjusted Net Profit * 3.9 3.3 19.0% % 4.3% 3.7% Adjusted EBITDA 10.0 9.9 1.0% % 10.9% 11.3% Net operating cash flow 15.0 (22.9) A REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 S
Slide 11: P&L highlights by Segment
P&L highlights by Segment M USD Revenue Q1’2026 Q1’2025 Δ EBITDA* Q1’2026 Q1’2025 Δ Group 91.5M 87.7M 4% Group ** 10.0M 9.9M 1% Juice Solutions 71.5M 75.4M (5%) Juice Solutions 8.3M 9.7M (15%) SIS 19.7M 12.0M 64% SIS 3.6M 1.8M 95% Solos 0.4M 0.3M 34% Solos (0.3M) (0.2M) - REIMAGINING NATURE INTO HEA
Slide 12: Balance sheet highlights
Balance sheet highlights M USD Q1’2026 2025 Assets Current Assets 309.4 240.2 Non-Current Assets 126.8 91.1 Total Assets 436.2 331.3 Liabilities and Equity Current Liabilities 178.2 187.5 Non-Current Liabilities 19.2 23.0 Equity 238.8 120.8 Total Liabilities and Equity 436.2 331.3 Ratios Working Cap
Slide 13: Our Recent Activities
Our Recent Activities Q1 REPORT MAY 2026 REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 0015
Slide 14: Successful synergetic integration
Acquired December Successful synergetic integration 2025 for $19M CROSS PROCUMENT SELLING HARMONIZATION Several projects Annnual saving in place starting from 2027 EXPANDING OPERATIONAL PORTFOLIO SYNERGIES A comprehensive Integration of flavoring offering global functions under development VALUE CRE
Slide 15: Penetrating botanical extraction market with Sylvestre acquisition
Acquired March 2026 for $31M Penetrating botanical extraction market with Sylvestre acquisition Solid legacy platform Cutting edge products Accelerated growth segments Established in 1992, with deep Broad portfolio of botanical Capitalizing on significant cross- expertise in Brazilian extracts. extr
Slide 16: Enhancing beverage and confectionary better-for-you solutions with Better Juice sugar reduction technology
Enhancing beverage and confectionary better-for-you solutions with Better Juice sugar reduction technology April 2026 Patented enzymatic technology converting sugars into healthy sweeteners and dietary fibers Value proposition 80% Maintaining nutrients & vitamins composition less sugar Preserving mo
Slide 17: VDB Acquisition a state-of-the-art blending facility to support future growth plans
VDB Acquisition a state-of-the-art blending facility to support future growth plans April 2026 Modern & highly valuable production assets Enables significant blending capacity expansion of ~30k MT Strategically located to serve customers across the European market REIMAGINING NATURE INTO HEALTHIER C
Slide 18: Enhancing R&D global capabilities with new state-of-the-art application labs
Enhancing R&D global capabilities with new state-of-the-art application labs January 2026 March 2026 Colors R&D Center in Slovenia Application labs in Spain & USA Supporting formulation & application capabilities Supporting creation capabilities across multiple addressing the accelerated market grow
Slide 19: Scaling footprint and production capabilities
Scaling footprint and production capabilities January 2026 April 2026 Valencia, Spain site Inauguration California, USA site Inauguration 16M liters | 10M bottles 15M liters with expansion potential REIMAGINING NATURE INTO HEALTHIER CREATIONS 05/11/2026 SLIDE 0021
Slide 20: Thank you
Thank you Get in touch ir@prodalim.com